ePatientFinder, M3 join to bring clinical trials to patients

ePatientFinder, which uses electronic health reacords (EHRs) in clinical trial recruitment, has partnered with M3 Inc. to include its information and website services to add an additional two million physicians to ePatientFinder's recruitment platform.

Currently, the lack of easily accessible information on clinical trials has led to a low referral rate by physicians to their patients that could potentially gain from such treatment.

"The ePatientFinder clinical trial recruitment solution aligns perfectly with M3's mission to educate and inform physicians, especially as it relates to giving them the tools they need to help their patients," said Aki Tomaru, CEO of M3.

Paring ePatientFinders EHR filtering processes and M3’s digital information health serviceswhich include daily updated clinical information and news, market research, ethical drug promotion, clinical development and clinic appointment services—may produce in an influx of patients ready to be included in the clinical trial process.

"With numerous EHR partners, our platform already includes access to millions of patient lives and tens of thousands of providers," said Tom Dorsett, CEO and President of ePatientFinder. "This partnership with M3 greatly expands our network of potential referring physicians, ensuring that they, too, will be aware of life-changing, or even life-saving, clinical trials that they—or their patients—likely would not have known about otherwise."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup